nodes	percent_of_prediction	percent_of_DWPC	metapath
Duloxetine—Protriptyline—Carbamazepine—epilepsy syndrome	0.142	1	CrCrCtD
Duloxetine—SLC6A4—epilepsy syndrome	0.0777	0.405	CbGaD
Duloxetine—bipolar disorder—Oxcarbazepine—epilepsy syndrome	0.0629	0.162	CpDpCtD
Duloxetine—bipolar disorder—Lamotrigine—epilepsy syndrome	0.0629	0.162	CpDpCtD
Duloxetine—HTR2A—epilepsy syndrome	0.0597	0.311	CbGaD
Duloxetine—CYP2D6—epilepsy syndrome	0.0546	0.284	CbGaD
Duloxetine—bipolar disorder—Topiramate—epilepsy syndrome	0.0535	0.138	CpDpCtD
Duloxetine—endogenous depression—Valproic Acid—epilepsy syndrome	0.051	0.132	CpDpCtD
Duloxetine—bipolar disorder—Carbamazepine—epilepsy syndrome	0.0477	0.123	CpDpCtD
Duloxetine—bipolar disorder—Valproic Acid—epilepsy syndrome	0.0405	0.105	CpDpCtD
Duloxetine—bipolar disorder—Clonazepam—epilepsy syndrome	0.0381	0.0984	CpDpCtD
Duloxetine—bipolar disorder—Gabapentin—epilepsy syndrome	0.0307	0.0793	CpDpCtD
Duloxetine—CYP1A2—Carbamazepine—epilepsy syndrome	0.00999	0.178	CbGbCtD
Duloxetine—CYP1A2—Primidone—epilepsy syndrome	0.00932	0.166	CbGbCtD
Duloxetine—CYP1A2—Propofol—epilepsy syndrome	0.00835	0.149	CbGbCtD
Duloxetine—CYP1A2—Phenobarbital—epilepsy syndrome	0.00798	0.142	CbGbCtD
Duloxetine—CYP1A2—Diazepam—epilepsy syndrome	0.00757	0.135	CbGbCtD
Duloxetine—CYP2D6—Propofol—epilepsy syndrome	0.00688	0.123	CbGbCtD
Duloxetine—CYP1A2—Valproic Acid—epilepsy syndrome	0.00597	0.106	CbGbCtD
Duloxetine—HTR2A—phrenic nerve—epilepsy syndrome	0.00295	0.0813	CbGeAlD
Duloxetine—SLC6A2—locus ceruleus—epilepsy syndrome	0.00219	0.0604	CbGeAlD
Duloxetine—HTR6—ganglion—epilepsy syndrome	0.00134	0.037	CbGeAlD
Duloxetine—HTR2A—locus ceruleus—epilepsy syndrome	0.00132	0.0363	CbGeAlD
Duloxetine—SLC6A3—telencephalic ventricle—epilepsy syndrome	0.00129	0.0355	CbGeAlD
Duloxetine—HTR2C—telencephalic ventricle—epilepsy syndrome	0.00124	0.0343	CbGeAlD
Duloxetine—SLC6A2—autonomic nervous system—epilepsy syndrome	0.00116	0.0321	CbGeAlD
Duloxetine—HTR2A—cerebellar cortex—epilepsy syndrome	0.00107	0.0296	CbGeAlD
Duloxetine—HTR2A—vagus nerve—epilepsy syndrome	0.00101	0.0278	CbGeAlD
Duloxetine—SLC6A3—ganglion—epilepsy syndrome	0.000801	0.0221	CbGeAlD
Duloxetine—NPY1R—forebrain—epilepsy syndrome	0.000799	0.022	CbGeAlD
Duloxetine—HTR2C—ganglion—epilepsy syndrome	0.000775	0.0214	CbGeAlD
Duloxetine—HTR2A—pons—epilepsy syndrome	0.000759	0.0209	CbGeAlD
Duloxetine—NPY1R—telencephalon—epilepsy syndrome	0.000735	0.0203	CbGeAlD
Duloxetine—SLC6A4—ganglion—epilepsy syndrome	0.000734	0.0202	CbGeAlD
Duloxetine—HTR2A—autonomic nervous system—epilepsy syndrome	0.0007	0.0193	CbGeAlD
Duloxetine—SLC6A2—ganglion—epilepsy syndrome	0.000647	0.0178	CbGeAlD
Duloxetine—HTR2A—telencephalic ventricle—epilepsy syndrome	0.000624	0.0172	CbGeAlD
Duloxetine—SLC6A3—hindbrain—epilepsy syndrome	0.000608	0.0168	CbGeAlD
Duloxetine—HTR6—forebrain—epilepsy syndrome	0.000562	0.0155	CbGeAlD
Duloxetine—SLC6A4—hindbrain—epilepsy syndrome	0.000557	0.0154	CbGeAlD
Duloxetine—HTR6—telencephalon—epilepsy syndrome	0.000517	0.0143	CbGeAlD
Duloxetine—NPY1R—head—epilepsy syndrome	0.000458	0.0126	CbGeAlD
Duloxetine—NPY1R—nervous system—epilepsy syndrome	0.000434	0.012	CbGeAlD
Duloxetine—NPY1R—central nervous system—epilepsy syndrome	0.000418	0.0115	CbGeAlD
Duloxetine—HTR2A—ganglion—epilepsy syndrome	0.000389	0.0107	CbGeAlD
Duloxetine—SLC6A3—brainstem—epilepsy syndrome	0.000348	0.00961	CbGeAlD
Duloxetine—HTR2C—brainstem—epilepsy syndrome	0.000337	0.00928	CbGeAlD
Duloxetine—SLC6A3—forebrain—epilepsy syndrome	0.000336	0.00927	CbGeAlD
Duloxetine—NPY1R—brain—epilepsy syndrome	0.000332	0.00914	CbGeAlD
Duloxetine—HTR2C—forebrain—epilepsy syndrome	0.000325	0.00896	CbGeAlD
Duloxetine—HTR6—head—epilepsy syndrome	0.000322	0.00888	CbGeAlD
Duloxetine—SLC6A4—brainstem—epilepsy syndrome	0.000319	0.0088	CbGeAlD
Duloxetine—SLC6A3—telencephalon—epilepsy syndrome	0.000309	0.00852	CbGeAlD
Duloxetine—SLC6A4—forebrain—epilepsy syndrome	0.000308	0.00849	CbGeAlD
Duloxetine—HTR6—nervous system—epilepsy syndrome	0.000305	0.00842	CbGeAlD
Duloxetine—HTR2C—telencephalon—epilepsy syndrome	0.000299	0.00824	CbGeAlD
Duloxetine—HTR2A—hindbrain—epilepsy syndrome	0.000295	0.00813	CbGeAlD
Duloxetine—HTR6—central nervous system—epilepsy syndrome	0.000294	0.0081	CbGeAlD
Duloxetine—SLC6A4—telencephalon—epilepsy syndrome	0.000283	0.00781	CbGeAlD
Duloxetine—SLC6A2—brainstem—epilepsy syndrome	0.000281	0.00775	CbGeAlD
Duloxetine—SLC6A2—forebrain—epilepsy syndrome	0.000271	0.00748	CbGeAlD
Duloxetine—CYP2D6—hindbrain—epilepsy syndrome	0.000268	0.0074	CbGeAlD
Duloxetine—SLC6A2—telencephalon—epilepsy syndrome	0.000249	0.00688	CbGeAlD
Duloxetine—HTR2C—medulla oblongata—epilepsy syndrome	0.000235	0.00647	CbGeAlD
Duloxetine—HTR6—brain—epilepsy syndrome	0.000233	0.00643	CbGeAlD
Duloxetine—SLC6A3—midbrain—epilepsy syndrome	0.000222	0.00612	CbGeAlD
Duloxetine—Naphazoline—ADRA2A—epilepsy syndrome	0.000217	0.148	CrCbGaD
Duloxetine—SLC6A3—spinal cord—epilepsy syndrome	0.000217	0.00597	CbGeAlD
Duloxetine—HTR2C—midbrain—epilepsy syndrome	0.000215	0.00592	CbGeAlD
Duloxetine—HTR2C—spinal cord—epilepsy syndrome	0.000209	0.00577	CbGeAlD
Duloxetine—SLC6A4—midbrain—epilepsy syndrome	0.000203	0.00561	CbGeAlD
Duloxetine—SLC6A4—spinal cord—epilepsy syndrome	0.000198	0.00547	CbGeAlD
Duloxetine—SLC6A2—medulla oblongata—epilepsy syndrome	0.000196	0.0054	CbGeAlD
Duloxetine—SLC6A3—head—epilepsy syndrome	0.000193	0.00531	CbGeAlD
Duloxetine—HTR2C—head—epilepsy syndrome	0.000186	0.00513	CbGeAlD
Duloxetine—SLC6A3—nervous system—epilepsy syndrome	0.000183	0.00503	CbGeAlD
Duloxetine—HTR2C—nervous system—epilepsy syndrome	0.000176	0.00486	CbGeAlD
Duloxetine—SLC6A4—head—epilepsy syndrome	0.000176	0.00486	CbGeAlD
Duloxetine—SLC6A3—central nervous system—epilepsy syndrome	0.000176	0.00485	CbGeAlD
Duloxetine—SLC6A3—cerebellum—epilepsy syndrome	0.000172	0.00474	CbGeAlD
Duloxetine—HTR2C—central nervous system—epilepsy syndrome	0.00017	0.00468	CbGeAlD
Duloxetine—HTR2A—brainstem—epilepsy syndrome	0.000169	0.00466	CbGeAlD
Duloxetine—SLC6A4—nervous system—epilepsy syndrome	0.000167	0.00461	CbGeAlD
Duloxetine—HTR2A—forebrain—epilepsy syndrome	0.000163	0.0045	CbGeAlD
Duloxetine—SLC6A4—central nervous system—epilepsy syndrome	0.000161	0.00444	CbGeAlD
Duloxetine—SLC6A2—head—epilepsy syndrome	0.000155	0.00428	CbGeAlD
Duloxetine—CYP2D6—brainstem—epilepsy syndrome	0.000154	0.00424	CbGeAlD
Duloxetine—HTR2A—telencephalon—epilepsy syndrome	0.00015	0.00413	CbGeAlD
Duloxetine—Protriptyline—SLC6A4—epilepsy syndrome	0.000149	0.102	CrCbGaD
Duloxetine—CYP2D6—forebrain—epilepsy syndrome	0.000149	0.0041	CbGeAlD
Duloxetine—SLC6A2—nervous system—epilepsy syndrome	0.000147	0.00406	CbGeAlD
Duloxetine—SLC6A2—central nervous system—epilepsy syndrome	0.000142	0.00391	CbGeAlD
Duloxetine—SLC6A3—brain—epilepsy syndrome	0.00014	0.00385	CbGeAlD
Duloxetine—CYP2D6—telencephalon—epilepsy syndrome	0.000137	0.00377	CbGeAlD
Duloxetine—HTR2C—brain—epilepsy syndrome	0.000135	0.00372	CbGeAlD
Duloxetine—SLC6A4—brain—epilepsy syndrome	0.000128	0.00352	CbGeAlD
Duloxetine—HTR2A—medulla oblongata—epilepsy syndrome	0.000118	0.00325	CbGeAlD
Duloxetine—SLC6A2—brain—epilepsy syndrome	0.000113	0.0031	CbGeAlD
Duloxetine—Cinacalcet—CYP2D6—epilepsy syndrome	0.000112	0.0763	CrCbGaD
Duloxetine—HTR2A—midbrain—epilepsy syndrome	0.000108	0.00297	CbGeAlD
Duloxetine—HTR2A—spinal cord—epilepsy syndrome	0.000105	0.0029	CbGeAlD
Duloxetine—Protriptyline—CYP2D6—epilepsy syndrome	0.000105	0.0714	CrCbGaD
Duloxetine—Fluoxetine—SLC6A4—epilepsy syndrome	0.000102	0.0693	CrCbGaD
Duloxetine—Fluoxetine—CYP2C19—epilepsy syndrome	9.65e-05	0.0657	CrCbGaD
Duloxetine—HTR2A—head—epilepsy syndrome	9.34e-05	0.00257	CbGeAlD
Duloxetine—HTR2A—nervous system—epilepsy syndrome	8.85e-05	0.00244	CbGeAlD
Duloxetine—HTR2A—central nervous system—epilepsy syndrome	8.52e-05	0.00235	CbGeAlD
Duloxetine—CYP2D6—head—epilepsy syndrome	8.5e-05	0.00234	CbGeAlD
Duloxetine—HTR2A—cerebellum—epilepsy syndrome	8.33e-05	0.0023	CbGeAlD
Duloxetine—CYP2D6—nervous system—epilepsy syndrome	8.06e-05	0.00222	CbGeAlD
Duloxetine—Fluoxetine—HTR2A—epilepsy syndrome	7.82e-05	0.0533	CrCbGaD
Duloxetine—CYP2D6—central nervous system—epilepsy syndrome	7.76e-05	0.00214	CbGeAlD
Duloxetine—CYP2D6—cerebellum—epilepsy syndrome	7.59e-05	0.00209	CbGeAlD
Duloxetine—Protriptyline—ABCB1—epilepsy syndrome	7.48e-05	0.051	CrCbGaD
Duloxetine—Fluoxetine—CYP2D6—epilepsy syndrome	7.15e-05	0.0487	CrCbGaD
Duloxetine—HTR2A—brain—epilepsy syndrome	6.76e-05	0.00187	CbGeAlD
Duloxetine—Atomoxetine—SLC6A4—epilepsy syndrome	6.54e-05	0.0446	CrCbGaD
Duloxetine—Atomoxetine—CYP2C19—epilepsy syndrome	6.2e-05	0.0422	CrCbGaD
Duloxetine—CYP2D6—brain—epilepsy syndrome	6.16e-05	0.0017	CbGeAlD
Duloxetine—Propranolol—CYP2C19—epilepsy syndrome	5.89e-05	0.0401	CrCbGaD
Duloxetine—Fluoxetine—ALB—epilepsy syndrome	5.35e-05	0.0365	CrCbGaD
Duloxetine—Fluoxetine—ABCB1—epilepsy syndrome	5.11e-05	0.0348	CrCbGaD
Duloxetine—Atomoxetine—HTR2A—epilepsy syndrome	5.03e-05	0.0342	CrCbGaD
Duloxetine—Atomoxetine—CYP2D6—epilepsy syndrome	4.6e-05	0.0313	CrCbGaD
Duloxetine—Propranolol—CYP2D6—epilepsy syndrome	4.37e-05	0.0297	CrCbGaD
Duloxetine—Propranolol—ABCB1—epilepsy syndrome	3.12e-05	0.0212	CrCbGaD
Duloxetine—Ill-defined disorder—Gabapentin—epilepsy syndrome	1.65e-05	0.000131	CcSEcCtD
Duloxetine—Dizziness—Zonisamide—epilepsy syndrome	1.65e-05	0.000131	CcSEcCtD
Duloxetine—Headache—Diazepam—epilepsy syndrome	1.65e-05	0.000131	CcSEcCtD
Duloxetine—Anxiety—Pregabalin—epilepsy syndrome	1.64e-05	0.00013	CcSEcCtD
Duloxetine—Diarrhoea—Clonazepam—epilepsy syndrome	1.64e-05	0.00013	CcSEcCtD
Duloxetine—Anaemia—Gabapentin—epilepsy syndrome	1.64e-05	0.00013	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Pregabalin—epilepsy syndrome	1.64e-05	0.00013	CcSEcCtD
Duloxetine—Asthenia—Carbamazepine—epilepsy syndrome	1.63e-05	0.00013	CcSEcCtD
Duloxetine—Agitation—Gabapentin—epilepsy syndrome	1.63e-05	0.00013	CcSEcCtD
Duloxetine—Diarrhoea—Phenytoin—epilepsy syndrome	1.63e-05	0.00013	CcSEcCtD
Duloxetine—Discomfort—Pregabalin—epilepsy syndrome	1.63e-05	0.000129	CcSEcCtD
Duloxetine—Nausea—Fosphenytoin—epilepsy syndrome	1.63e-05	0.000129	CcSEcCtD
Duloxetine—Diarrhoea—Oxcarbazepine—epilepsy syndrome	1.62e-05	0.000129	CcSEcCtD
Duloxetine—Erythema multiforme—Topiramate—epilepsy syndrome	1.62e-05	0.000129	CcSEcCtD
Duloxetine—Angioedema—Gabapentin—epilepsy syndrome	1.62e-05	0.000129	CcSEcCtD
Duloxetine—Hypersensitivity—Lamotrigine—epilepsy syndrome	1.62e-05	0.000129	CcSEcCtD
Duloxetine—Vomiting—Felbamate—epilepsy syndrome	1.62e-05	0.000128	CcSEcCtD
Duloxetine—Dry mouth—Pregabalin—epilepsy syndrome	1.61e-05	0.000128	CcSEcCtD
Duloxetine—Pruritus—Carbamazepine—epilepsy syndrome	1.61e-05	0.000128	CcSEcCtD
Duloxetine—Rash—Felbamate—epilepsy syndrome	1.6e-05	0.000127	CcSEcCtD
Duloxetine—Eye disorder—Topiramate—epilepsy syndrome	1.6e-05	0.000127	CcSEcCtD
Duloxetine—Dermatitis—Felbamate—epilepsy syndrome	1.6e-05	0.000127	CcSEcCtD
Duloxetine—Malaise—Gabapentin—epilepsy syndrome	1.6e-05	0.000127	CcSEcCtD
Duloxetine—Tinnitus—Topiramate—epilepsy syndrome	1.6e-05	0.000127	CcSEcCtD
Duloxetine—Vertigo—Gabapentin—epilepsy syndrome	1.59e-05	0.000127	CcSEcCtD
Duloxetine—Headache—Felbamate—epilepsy syndrome	1.59e-05	0.000127	CcSEcCtD
Duloxetine—Confusional state—Pregabalin—epilepsy syndrome	1.59e-05	0.000127	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Valproic Acid—epilepsy syndrome	1.59e-05	0.000126	CcSEcCtD
Duloxetine—Flushing—Topiramate—epilepsy syndrome	1.59e-05	0.000126	CcSEcCtD
Duloxetine—Cardiac disorder—Topiramate—epilepsy syndrome	1.59e-05	0.000126	CcSEcCtD
Duloxetine—Syncope—Gabapentin—epilepsy syndrome	1.59e-05	0.000126	CcSEcCtD
Duloxetine—Leukopenia—Gabapentin—epilepsy syndrome	1.59e-05	0.000126	CcSEcCtD
Duloxetine—Dizziness—Clonazepam—epilepsy syndrome	1.59e-05	0.000126	CcSEcCtD
Duloxetine—Nausea—Vigabatrin—epilepsy syndrome	1.58e-05	0.000126	CcSEcCtD
Duloxetine—Vomiting—Zonisamide—epilepsy syndrome	1.58e-05	0.000126	CcSEcCtD
Duloxetine—Insomnia—Valproic Acid—epilepsy syndrome	1.58e-05	0.000126	CcSEcCtD
Duloxetine—Anaphylactic shock—Pregabalin—epilepsy syndrome	1.58e-05	0.000125	CcSEcCtD
Duloxetine—Oedema—Pregabalin—epilepsy syndrome	1.58e-05	0.000125	CcSEcCtD
Duloxetine—Asthenia—Lamotrigine—epilepsy syndrome	1.58e-05	0.000125	CcSEcCtD
Duloxetine—Dizziness—Phenytoin—epilepsy syndrome	1.58e-05	0.000125	CcSEcCtD
Duloxetine—Rash—Zonisamide—epilepsy syndrome	1.57e-05	0.000125	CcSEcCtD
Duloxetine—Infection—Pregabalin—epilepsy syndrome	1.57e-05	0.000125	CcSEcCtD
Duloxetine—Paraesthesia—Valproic Acid—epilepsy syndrome	1.57e-05	0.000125	CcSEcCtD
Duloxetine—Palpitations—Gabapentin—epilepsy syndrome	1.57e-05	0.000125	CcSEcCtD
Duloxetine—Dermatitis—Zonisamide—epilepsy syndrome	1.57e-05	0.000125	CcSEcCtD
Duloxetine—Dizziness—Oxcarbazepine—epilepsy syndrome	1.57e-05	0.000125	CcSEcCtD
Duloxetine—Nausea—Diazepam—epilepsy syndrome	1.56e-05	0.000124	CcSEcCtD
Duloxetine—Loss of consciousness—Gabapentin—epilepsy syndrome	1.56e-05	0.000124	CcSEcCtD
Duloxetine—Headache—Zonisamide—epilepsy syndrome	1.56e-05	0.000124	CcSEcCtD
Duloxetine—Diarrhoea—Carbamazepine—epilepsy syndrome	1.56e-05	0.000124	CcSEcCtD
Duloxetine—Angiopathy—Topiramate—epilepsy syndrome	1.56e-05	0.000124	CcSEcCtD
Duloxetine—Pruritus—Lamotrigine—epilepsy syndrome	1.55e-05	0.000124	CcSEcCtD
Duloxetine—Shock—Pregabalin—epilepsy syndrome	1.55e-05	0.000123	CcSEcCtD
Duloxetine—Somnolence—Valproic Acid—epilepsy syndrome	1.55e-05	0.000123	CcSEcCtD
Duloxetine—Immune system disorder—Topiramate—epilepsy syndrome	1.55e-05	0.000123	CcSEcCtD
Duloxetine—Nervous system disorder—Pregabalin—epilepsy syndrome	1.55e-05	0.000123	CcSEcCtD
Duloxetine—Cough—Gabapentin—epilepsy syndrome	1.55e-05	0.000123	CcSEcCtD
Duloxetine—Thrombocytopenia—Pregabalin—epilepsy syndrome	1.55e-05	0.000123	CcSEcCtD
Duloxetine—Mediastinal disorder—Topiramate—epilepsy syndrome	1.54e-05	0.000123	CcSEcCtD
Duloxetine—Tachycardia—Pregabalin—epilepsy syndrome	1.54e-05	0.000122	CcSEcCtD
Duloxetine—Chills—Topiramate—epilepsy syndrome	1.54e-05	0.000122	CcSEcCtD
Duloxetine—Dyspepsia—Valproic Acid—epilepsy syndrome	1.54e-05	0.000122	CcSEcCtD
Duloxetine—Convulsion—Gabapentin—epilepsy syndrome	1.54e-05	0.000122	CcSEcCtD
Duloxetine—Skin disorder—Pregabalin—epilepsy syndrome	1.53e-05	0.000122	CcSEcCtD
Duloxetine—Hypertension—Gabapentin—epilepsy syndrome	1.53e-05	0.000122	CcSEcCtD
Duloxetine—Hyperhidrosis—Pregabalin—epilepsy syndrome	1.53e-05	0.000121	CcSEcCtD
Duloxetine—Vomiting—Clonazepam—epilepsy syndrome	1.52e-05	0.000121	CcSEcCtD
Duloxetine—Decreased appetite—Valproic Acid—epilepsy syndrome	1.52e-05	0.000121	CcSEcCtD
Duloxetine—Alopecia—Topiramate—epilepsy syndrome	1.51e-05	0.00012	CcSEcCtD
Duloxetine—Vomiting—Phenytoin—epilepsy syndrome	1.51e-05	0.00012	CcSEcCtD
Duloxetine—Rash—Clonazepam—epilepsy syndrome	1.51e-05	0.00012	CcSEcCtD
Duloxetine—Dermatitis—Clonazepam—epilepsy syndrome	1.51e-05	0.00012	CcSEcCtD
Duloxetine—Myalgia—Gabapentin—epilepsy syndrome	1.51e-05	0.00012	CcSEcCtD
Duloxetine—Chest pain—Gabapentin—epilepsy syndrome	1.51e-05	0.00012	CcSEcCtD
Duloxetine—Arthralgia—Gabapentin—epilepsy syndrome	1.51e-05	0.00012	CcSEcCtD
Duloxetine—Nausea—Felbamate—epilepsy syndrome	1.51e-05	0.00012	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Valproic Acid—epilepsy syndrome	1.51e-05	0.00012	CcSEcCtD
Duloxetine—Vomiting—Oxcarbazepine—epilepsy syndrome	1.51e-05	0.00012	CcSEcCtD
Duloxetine—Fatigue—Valproic Acid—epilepsy syndrome	1.51e-05	0.00012	CcSEcCtD
Duloxetine—Anxiety—Gabapentin—epilepsy syndrome	1.5e-05	0.00012	CcSEcCtD
Duloxetine—Anorexia—Pregabalin—epilepsy syndrome	1.5e-05	0.00012	CcSEcCtD
Duloxetine—Dizziness—Carbamazepine—epilepsy syndrome	1.5e-05	0.00012	CcSEcCtD
Duloxetine—Diarrhoea—Lamotrigine—epilepsy syndrome	1.5e-05	0.00012	CcSEcCtD
Duloxetine—Headache—Clonazepam—epilepsy syndrome	1.5e-05	0.000119	CcSEcCtD
Duloxetine—Rash—Phenytoin—epilepsy syndrome	1.5e-05	0.000119	CcSEcCtD
Duloxetine—Mental disorder—Topiramate—epilepsy syndrome	1.5e-05	0.000119	CcSEcCtD
Duloxetine—Dermatitis—Phenytoin—epilepsy syndrome	1.5e-05	0.000119	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Gabapentin—epilepsy syndrome	1.5e-05	0.000119	CcSEcCtD
Duloxetine—Rash—Oxcarbazepine—epilepsy syndrome	1.49e-05	0.000119	CcSEcCtD
Duloxetine—Pain—Valproic Acid—epilepsy syndrome	1.49e-05	0.000119	CcSEcCtD
Duloxetine—Constipation—Valproic Acid—epilepsy syndrome	1.49e-05	0.000119	CcSEcCtD
Duloxetine—Dermatitis—Oxcarbazepine—epilepsy syndrome	1.49e-05	0.000119	CcSEcCtD
Duloxetine—Headache—Phenytoin—epilepsy syndrome	1.49e-05	0.000119	CcSEcCtD
Duloxetine—Erythema—Topiramate—epilepsy syndrome	1.49e-05	0.000119	CcSEcCtD
Duloxetine—Malnutrition—Topiramate—epilepsy syndrome	1.49e-05	0.000119	CcSEcCtD
Duloxetine—Discomfort—Gabapentin—epilepsy syndrome	1.49e-05	0.000119	CcSEcCtD
Duloxetine—Headache—Oxcarbazepine—epilepsy syndrome	1.48e-05	0.000118	CcSEcCtD
Duloxetine—Nausea—Zonisamide—epilepsy syndrome	1.48e-05	0.000117	CcSEcCtD
Duloxetine—Dry mouth—Gabapentin—epilepsy syndrome	1.48e-05	0.000117	CcSEcCtD
Duloxetine—Flatulence—Topiramate—epilepsy syndrome	1.47e-05	0.000117	CcSEcCtD
Duloxetine—Tension—Topiramate—epilepsy syndrome	1.46e-05	0.000116	CcSEcCtD
Duloxetine—Dysgeusia—Topiramate—epilepsy syndrome	1.46e-05	0.000116	CcSEcCtD
Duloxetine—Confusional state—Gabapentin—epilepsy syndrome	1.46e-05	0.000116	CcSEcCtD
Duloxetine—Dizziness—Lamotrigine—epilepsy syndrome	1.45e-05	0.000116	CcSEcCtD
Duloxetine—Nervousness—Topiramate—epilepsy syndrome	1.45e-05	0.000115	CcSEcCtD
Duloxetine—Anaphylactic shock—Gabapentin—epilepsy syndrome	1.45e-05	0.000115	CcSEcCtD
Duloxetine—Oedema—Gabapentin—epilepsy syndrome	1.45e-05	0.000115	CcSEcCtD
Duloxetine—Vomiting—Carbamazepine—epilepsy syndrome	1.45e-05	0.000115	CcSEcCtD
Duloxetine—Back pain—Topiramate—epilepsy syndrome	1.44e-05	0.000115	CcSEcCtD
Duloxetine—Feeling abnormal—Valproic Acid—epilepsy syndrome	1.44e-05	0.000114	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Pregabalin—epilepsy syndrome	1.44e-05	0.000114	CcSEcCtD
Duloxetine—Infection—Gabapentin—epilepsy syndrome	1.44e-05	0.000114	CcSEcCtD
Duloxetine—Muscle spasms—Topiramate—epilepsy syndrome	1.43e-05	0.000114	CcSEcCtD
Duloxetine—Rash—Carbamazepine—epilepsy syndrome	1.43e-05	0.000114	CcSEcCtD
Duloxetine—Dermatitis—Carbamazepine—epilepsy syndrome	1.43e-05	0.000114	CcSEcCtD
Duloxetine—Gastrointestinal pain—Valproic Acid—epilepsy syndrome	1.43e-05	0.000114	CcSEcCtD
Duloxetine—Insomnia—Pregabalin—epilepsy syndrome	1.43e-05	0.000114	CcSEcCtD
Duloxetine—Nausea—Clonazepam—epilepsy syndrome	1.42e-05	0.000113	CcSEcCtD
Duloxetine—Headache—Carbamazepine—epilepsy syndrome	1.42e-05	0.000113	CcSEcCtD
Duloxetine—Shock—Gabapentin—epilepsy syndrome	1.42e-05	0.000113	CcSEcCtD
Duloxetine—Nervous system disorder—Gabapentin—epilepsy syndrome	1.42e-05	0.000113	CcSEcCtD
Duloxetine—Paraesthesia—Pregabalin—epilepsy syndrome	1.42e-05	0.000113	CcSEcCtD
Duloxetine—Thrombocytopenia—Gabapentin—epilepsy syndrome	1.42e-05	0.000113	CcSEcCtD
Duloxetine—Nausea—Phenytoin—epilepsy syndrome	1.41e-05	0.000112	CcSEcCtD
Duloxetine—Tachycardia—Gabapentin—epilepsy syndrome	1.41e-05	0.000112	CcSEcCtD
Duloxetine—Nausea—Oxcarbazepine—epilepsy syndrome	1.41e-05	0.000112	CcSEcCtD
Duloxetine—Vision blurred—Topiramate—epilepsy syndrome	1.41e-05	0.000112	CcSEcCtD
Duloxetine—Skin disorder—Gabapentin—epilepsy syndrome	1.41e-05	0.000112	CcSEcCtD
Duloxetine—Somnolence—Pregabalin—epilepsy syndrome	1.4e-05	0.000112	CcSEcCtD
Duloxetine—Hyperhidrosis—Gabapentin—epilepsy syndrome	1.4e-05	0.000111	CcSEcCtD
Duloxetine—Tremor—Topiramate—epilepsy syndrome	1.4e-05	0.000111	CcSEcCtD
Duloxetine—Vomiting—Lamotrigine—epilepsy syndrome	1.4e-05	0.000111	CcSEcCtD
Duloxetine—Urticaria—Valproic Acid—epilepsy syndrome	1.39e-05	0.00011	CcSEcCtD
Duloxetine—Rash—Lamotrigine—epilepsy syndrome	1.39e-05	0.00011	CcSEcCtD
Duloxetine—Ill-defined disorder—Topiramate—epilepsy syndrome	1.38e-05	0.00011	CcSEcCtD
Duloxetine—Dermatitis—Lamotrigine—epilepsy syndrome	1.38e-05	0.00011	CcSEcCtD
Duloxetine—Abdominal pain—Valproic Acid—epilepsy syndrome	1.38e-05	0.00011	CcSEcCtD
Duloxetine—Body temperature increased—Valproic Acid—epilepsy syndrome	1.38e-05	0.00011	CcSEcCtD
Duloxetine—Anorexia—Gabapentin—epilepsy syndrome	1.38e-05	0.00011	CcSEcCtD
Duloxetine—Anaemia—Topiramate—epilepsy syndrome	1.38e-05	0.00011	CcSEcCtD
Duloxetine—Headache—Lamotrigine—epilepsy syndrome	1.38e-05	0.000109	CcSEcCtD
Duloxetine—Decreased appetite—Pregabalin—epilepsy syndrome	1.37e-05	0.000109	CcSEcCtD
Duloxetine—Agitation—Topiramate—epilepsy syndrome	1.37e-05	0.000109	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Pregabalin—epilepsy syndrome	1.36e-05	0.000108	CcSEcCtD
Duloxetine—Fatigue—Pregabalin—epilepsy syndrome	1.36e-05	0.000108	CcSEcCtD
Duloxetine—Nausea—Carbamazepine—epilepsy syndrome	1.35e-05	0.000107	CcSEcCtD
Duloxetine—Pain—Pregabalin—epilepsy syndrome	1.35e-05	0.000107	CcSEcCtD
Duloxetine—Constipation—Pregabalin—epilepsy syndrome	1.35e-05	0.000107	CcSEcCtD
Duloxetine—Malaise—Topiramate—epilepsy syndrome	1.35e-05	0.000107	CcSEcCtD
Duloxetine—Vertigo—Topiramate—epilepsy syndrome	1.34e-05	0.000107	CcSEcCtD
Duloxetine—Syncope—Topiramate—epilepsy syndrome	1.34e-05	0.000106	CcSEcCtD
Duloxetine—Leukopenia—Topiramate—epilepsy syndrome	1.34e-05	0.000106	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Gabapentin—epilepsy syndrome	1.32e-05	0.000105	CcSEcCtD
Duloxetine—Palpitations—Topiramate—epilepsy syndrome	1.32e-05	0.000105	CcSEcCtD
Duloxetine—Loss of consciousness—Topiramate—epilepsy syndrome	1.31e-05	0.000104	CcSEcCtD
Duloxetine—Insomnia—Gabapentin—epilepsy syndrome	1.31e-05	0.000104	CcSEcCtD
Duloxetine—Nausea—Lamotrigine—epilepsy syndrome	1.31e-05	0.000104	CcSEcCtD
Duloxetine—Cough—Topiramate—epilepsy syndrome	1.3e-05	0.000104	CcSEcCtD
Duloxetine—Feeling abnormal—Pregabalin—epilepsy syndrome	1.3e-05	0.000103	CcSEcCtD
Duloxetine—Paraesthesia—Gabapentin—epilepsy syndrome	1.3e-05	0.000103	CcSEcCtD
Duloxetine—Convulsion—Topiramate—epilepsy syndrome	1.29e-05	0.000103	CcSEcCtD
Duloxetine—Gastrointestinal pain—Pregabalin—epilepsy syndrome	1.29e-05	0.000103	CcSEcCtD
Duloxetine—Hypertension—Topiramate—epilepsy syndrome	1.29e-05	0.000102	CcSEcCtD
Duloxetine—Somnolence—Gabapentin—epilepsy syndrome	1.29e-05	0.000102	CcSEcCtD
Duloxetine—Hypersensitivity—Valproic Acid—epilepsy syndrome	1.29e-05	0.000102	CcSEcCtD
Duloxetine—Dyspepsia—Gabapentin—epilepsy syndrome	1.27e-05	0.000101	CcSEcCtD
Duloxetine—Arthralgia—Topiramate—epilepsy syndrome	1.27e-05	0.000101	CcSEcCtD
Duloxetine—Chest pain—Topiramate—epilepsy syndrome	1.27e-05	0.000101	CcSEcCtD
Duloxetine—Myalgia—Topiramate—epilepsy syndrome	1.27e-05	0.000101	CcSEcCtD
Duloxetine—Anxiety—Topiramate—epilepsy syndrome	1.27e-05	0.000101	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Topiramate—epilepsy syndrome	1.26e-05	0.0001	CcSEcCtD
Duloxetine—Decreased appetite—Gabapentin—epilepsy syndrome	1.26e-05	0.0001	CcSEcCtD
Duloxetine—Discomfort—Topiramate—epilepsy syndrome	1.26e-05	9.98e-05	CcSEcCtD
Duloxetine—Urticaria—Pregabalin—epilepsy syndrome	1.25e-05	9.97e-05	CcSEcCtD
Duloxetine—Asthenia—Valproic Acid—epilepsy syndrome	1.25e-05	9.96e-05	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Gabapentin—epilepsy syndrome	1.25e-05	9.93e-05	CcSEcCtD
Duloxetine—Fatigue—Gabapentin—epilepsy syndrome	1.25e-05	9.92e-05	CcSEcCtD
Duloxetine—Body temperature increased—Pregabalin—epilepsy syndrome	1.25e-05	9.92e-05	CcSEcCtD
Duloxetine—Abdominal pain—Pregabalin—epilepsy syndrome	1.25e-05	9.92e-05	CcSEcCtD
Duloxetine—Dry mouth—Topiramate—epilepsy syndrome	1.24e-05	9.88e-05	CcSEcCtD
Duloxetine—Pain—Gabapentin—epilepsy syndrome	1.24e-05	9.84e-05	CcSEcCtD
Duloxetine—Constipation—Gabapentin—epilepsy syndrome	1.24e-05	9.84e-05	CcSEcCtD
Duloxetine—Pruritus—Valproic Acid—epilepsy syndrome	1.24e-05	9.82e-05	CcSEcCtD
Duloxetine—Confusional state—Topiramate—epilepsy syndrome	1.23e-05	9.76e-05	CcSEcCtD
Duloxetine—Oedema—Topiramate—epilepsy syndrome	1.22e-05	9.68e-05	CcSEcCtD
Duloxetine—Infection—Topiramate—epilepsy syndrome	1.21e-05	9.62e-05	CcSEcCtD
Duloxetine—Shock—Topiramate—epilepsy syndrome	1.2e-05	9.52e-05	CcSEcCtD
Duloxetine—Diarrhoea—Valproic Acid—epilepsy syndrome	1.19e-05	9.5e-05	CcSEcCtD
Duloxetine—Nervous system disorder—Topiramate—epilepsy syndrome	1.19e-05	9.49e-05	CcSEcCtD
Duloxetine—Feeling abnormal—Gabapentin—epilepsy syndrome	1.19e-05	9.48e-05	CcSEcCtD
Duloxetine—Thrombocytopenia—Topiramate—epilepsy syndrome	1.19e-05	9.48e-05	CcSEcCtD
Duloxetine—Tachycardia—Topiramate—epilepsy syndrome	1.19e-05	9.45e-05	CcSEcCtD
Duloxetine—Gastrointestinal pain—Gabapentin—epilepsy syndrome	1.18e-05	9.41e-05	CcSEcCtD
Duloxetine—Skin disorder—Topiramate—epilepsy syndrome	1.18e-05	9.4e-05	CcSEcCtD
Duloxetine—Hyperhidrosis—Topiramate—epilepsy syndrome	1.18e-05	9.36e-05	CcSEcCtD
Duloxetine—Hypersensitivity—Pregabalin—epilepsy syndrome	1.16e-05	9.25e-05	CcSEcCtD
Duloxetine—Anorexia—Topiramate—epilepsy syndrome	1.16e-05	9.23e-05	CcSEcCtD
Duloxetine—Dizziness—Valproic Acid—epilepsy syndrome	1.15e-05	9.18e-05	CcSEcCtD
Duloxetine—Urticaria—Gabapentin—epilepsy syndrome	1.15e-05	9.14e-05	CcSEcCtD
Duloxetine—Abdominal pain—Gabapentin—epilepsy syndrome	1.14e-05	9.1e-05	CcSEcCtD
Duloxetine—Body temperature increased—Gabapentin—epilepsy syndrome	1.14e-05	9.1e-05	CcSEcCtD
Duloxetine—Asthenia—Pregabalin—epilepsy syndrome	1.13e-05	9e-05	CcSEcCtD
Duloxetine—Pruritus—Pregabalin—epilepsy syndrome	1.12e-05	8.88e-05	CcSEcCtD
Duloxetine—Vomiting—Valproic Acid—epilepsy syndrome	1.11e-05	8.83e-05	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Topiramate—epilepsy syndrome	1.11e-05	8.82e-05	CcSEcCtD
Duloxetine—Insomnia—Topiramate—epilepsy syndrome	1.1e-05	8.76e-05	CcSEcCtD
Duloxetine—Rash—Valproic Acid—epilepsy syndrome	1.1e-05	8.75e-05	CcSEcCtD
Duloxetine—Dermatitis—Valproic Acid—epilepsy syndrome	1.1e-05	8.74e-05	CcSEcCtD
Duloxetine—Headache—Valproic Acid—epilepsy syndrome	1.09e-05	8.7e-05	CcSEcCtD
Duloxetine—Paraesthesia—Topiramate—epilepsy syndrome	1.09e-05	8.69e-05	CcSEcCtD
Duloxetine—Somnolence—Topiramate—epilepsy syndrome	1.08e-05	8.61e-05	CcSEcCtD
Duloxetine—Diarrhoea—Pregabalin—epilepsy syndrome	1.08e-05	8.59e-05	CcSEcCtD
Duloxetine—Dyspepsia—Topiramate—epilepsy syndrome	1.07e-05	8.52e-05	CcSEcCtD
Duloxetine—Hypersensitivity—Gabapentin—epilepsy syndrome	1.07e-05	8.48e-05	CcSEcCtD
Duloxetine—Decreased appetite—Topiramate—epilepsy syndrome	1.06e-05	8.42e-05	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Topiramate—epilepsy syndrome	1.05e-05	8.36e-05	CcSEcCtD
Duloxetine—Fatigue—Topiramate—epilepsy syndrome	1.05e-05	8.35e-05	CcSEcCtD
Duloxetine—Dizziness—Pregabalin—epilepsy syndrome	1.04e-05	8.3e-05	CcSEcCtD
Duloxetine—Constipation—Topiramate—epilepsy syndrome	1.04e-05	8.28e-05	CcSEcCtD
Duloxetine—Pain—Topiramate—epilepsy syndrome	1.04e-05	8.28e-05	CcSEcCtD
Duloxetine—Asthenia—Gabapentin—epilepsy syndrome	1.04e-05	8.26e-05	CcSEcCtD
Duloxetine—Nausea—Valproic Acid—epilepsy syndrome	1.04e-05	8.25e-05	CcSEcCtD
Duloxetine—Pruritus—Gabapentin—epilepsy syndrome	1.02e-05	8.14e-05	CcSEcCtD
Duloxetine—Vomiting—Pregabalin—epilepsy syndrome	1e-05	7.98e-05	CcSEcCtD
Duloxetine—Feeling abnormal—Topiramate—epilepsy syndrome	1e-05	7.98e-05	CcSEcCtD
Duloxetine—Gastrointestinal pain—Topiramate—epilepsy syndrome	9.96e-06	7.92e-05	CcSEcCtD
Duloxetine—Rash—Pregabalin—epilepsy syndrome	9.95e-06	7.91e-05	CcSEcCtD
Duloxetine—Dermatitis—Pregabalin—epilepsy syndrome	9.94e-06	7.91e-05	CcSEcCtD
Duloxetine—Diarrhoea—Gabapentin—epilepsy syndrome	9.9e-06	7.87e-05	CcSEcCtD
Duloxetine—Headache—Pregabalin—epilepsy syndrome	9.89e-06	7.86e-05	CcSEcCtD
Duloxetine—Urticaria—Topiramate—epilepsy syndrome	9.68e-06	7.69e-05	CcSEcCtD
Duloxetine—Body temperature increased—Topiramate—epilepsy syndrome	9.63e-06	7.65e-05	CcSEcCtD
Duloxetine—Abdominal pain—Topiramate—epilepsy syndrome	9.63e-06	7.65e-05	CcSEcCtD
Duloxetine—Dizziness—Gabapentin—epilepsy syndrome	9.57e-06	7.61e-05	CcSEcCtD
Duloxetine—Nausea—Pregabalin—epilepsy syndrome	9.38e-06	7.45e-05	CcSEcCtD
Duloxetine—Vomiting—Gabapentin—epilepsy syndrome	9.2e-06	7.32e-05	CcSEcCtD
Duloxetine—Rash—Gabapentin—epilepsy syndrome	9.13e-06	7.26e-05	CcSEcCtD
Duloxetine—Dermatitis—Gabapentin—epilepsy syndrome	9.12e-06	7.25e-05	CcSEcCtD
Duloxetine—Headache—Gabapentin—epilepsy syndrome	9.07e-06	7.21e-05	CcSEcCtD
Duloxetine—Hypersensitivity—Topiramate—epilepsy syndrome	8.97e-06	7.13e-05	CcSEcCtD
Duloxetine—Asthenia—Topiramate—epilepsy syndrome	8.74e-06	6.95e-05	CcSEcCtD
Duloxetine—Pruritus—Topiramate—epilepsy syndrome	8.62e-06	6.85e-05	CcSEcCtD
Duloxetine—Nausea—Gabapentin—epilepsy syndrome	8.6e-06	6.84e-05	CcSEcCtD
Duloxetine—Diarrhoea—Topiramate—epilepsy syndrome	8.33e-06	6.62e-05	CcSEcCtD
Duloxetine—Dizziness—Topiramate—epilepsy syndrome	8.05e-06	6.4e-05	CcSEcCtD
Duloxetine—Vomiting—Topiramate—epilepsy syndrome	7.74e-06	6.16e-05	CcSEcCtD
Duloxetine—Rash—Topiramate—epilepsy syndrome	7.68e-06	6.1e-05	CcSEcCtD
Duloxetine—Dermatitis—Topiramate—epilepsy syndrome	7.67e-06	6.1e-05	CcSEcCtD
Duloxetine—Headache—Topiramate—epilepsy syndrome	7.63e-06	6.06e-05	CcSEcCtD
Duloxetine—Nausea—Topiramate—epilepsy syndrome	7.23e-06	5.75e-05	CcSEcCtD
Duloxetine—HTR2A—Signaling Pathways—CX3CR1—epilepsy syndrome	3.63e-06	6.15e-05	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—SRC—epilepsy syndrome	3.61e-06	6.13e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—HBEGF—epilepsy syndrome	3.59e-06	6.08e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CHRM2—epilepsy syndrome	3.56e-06	6.04e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—BDKRB1—epilepsy syndrome	3.56e-06	6.04e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CX3CL1—epilepsy syndrome	3.56e-06	6.04e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCR3—epilepsy syndrome	3.55e-06	6.03e-05	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—HTR2A—epilepsy syndrome	3.55e-06	6.02e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ALDH7A1—epilepsy syndrome	3.54e-06	6.01e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CACNA1A—epilepsy syndrome	3.54e-06	6.01e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PPP1R3C—epilepsy syndrome	3.53e-06	5.98e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GBE1—epilepsy syndrome	3.53e-06	5.98e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—AKT3—epilepsy syndrome	3.52e-06	5.97e-05	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—VEGFA—epilepsy syndrome	3.52e-06	5.97e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—POMC—epilepsy syndrome	3.5e-06	5.93e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CDC42—epilepsy syndrome	3.48e-06	5.9e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ST3GAL3—epilepsy syndrome	3.47e-06	5.88e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NPY—epilepsy syndrome	3.46e-06	5.87e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ATP2A2—epilepsy syndrome	3.46e-06	5.87e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—GABBR1—epilepsy syndrome	3.46e-06	5.87e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—epilepsy syndrome	3.45e-06	5.85e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—ADAM10—epilepsy syndrome	3.44e-06	5.83e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—CCL2—epilepsy syndrome	3.42e-06	5.8e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ADSL—epilepsy syndrome	3.4e-06	5.76e-05	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—AGT—epilepsy syndrome	3.37e-06	5.72e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—AVP—epilepsy syndrome	3.37e-06	5.71e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HSPB1—epilepsy syndrome	3.34e-06	5.67e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CRH—epilepsy syndrome	3.34e-06	5.67e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCL3—epilepsy syndrome	3.34e-06	5.67e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—OXT—epilepsy syndrome	3.34e-06	5.67e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CXCL2—epilepsy syndrome	3.34e-06	5.67e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GLUL—epilepsy syndrome	3.33e-06	5.65e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HRH3—epilepsy syndrome	3.32e-06	5.63e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ASAH1—epilepsy syndrome	3.32e-06	5.63e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CCR5—epilepsy syndrome	3.3e-06	5.59e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CACNA1D—epilepsy syndrome	3.27e-06	5.54e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—OPRM1—epilepsy syndrome	3.27e-06	5.54e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—S100B—epilepsy syndrome	3.25e-06	5.51e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—STXBP1—epilepsy syndrome	3.23e-06	5.47e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—HTR2A—epilepsy syndrome	3.23e-06	5.47e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—SOCS3—epilepsy syndrome	3.22e-06	5.46e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CDC42—epilepsy syndrome	3.21e-06	5.45e-05	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CCR5—epilepsy syndrome	3.15e-06	5.35e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NT5E—epilepsy syndrome	3.15e-06	5.33e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ALAD—epilepsy syndrome	3.15e-06	5.33e-05	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—PRKCB—epilepsy syndrome	3.11e-06	5.28e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—AVP—epilepsy syndrome	3.11e-06	5.27e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PTK2B—epilepsy syndrome	3.11e-06	5.27e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TSC1—epilepsy syndrome	3.11e-06	5.27e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCR3—epilepsy syndrome	3.09e-06	5.23e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—AGT—epilepsy syndrome	3.06e-06	5.19e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—TXNRD1—epilepsy syndrome	3.06e-06	5.18e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCR2—epilepsy syndrome	3.02e-06	5.12e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NTRK2—epilepsy syndrome	3.02e-06	5.12e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SST—epilepsy syndrome	3.02e-06	5.12e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NPY—epilepsy syndrome	3.01e-06	5.1e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ATP2A2—epilepsy syndrome	3.01e-06	5.1e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CACNA1A—epilepsy syndrome	3e-06	5.09e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ALDH7A1—epilepsy syndrome	3e-06	5.09e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—DUSP6—epilepsy syndrome	3e-06	5.08e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—AQP1—epilepsy syndrome	2.97e-06	5.03e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ADRA2A—epilepsy syndrome	2.96e-06	5.01e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PLAT—epilepsy syndrome	2.94e-06	4.99e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—HES1—epilepsy syndrome	2.94e-06	4.99e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ST3GAL3—epilepsy syndrome	2.94e-06	4.98e-05	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—AGT—epilepsy syndrome	2.93e-06	4.96e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HSPB1—epilepsy syndrome	2.9e-06	4.92e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CRH—epilepsy syndrome	2.9e-06	4.92e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—OXT—epilepsy syndrome	2.9e-06	4.92e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CXCL2—epilepsy syndrome	2.9e-06	4.92e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCL3—epilepsy syndrome	2.9e-06	4.92e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ADSL—epilepsy syndrome	2.88e-06	4.88e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CCR5—epilepsy syndrome	2.86e-06	4.85e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—FYN—epilepsy syndrome	2.86e-06	4.85e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—H2AFX—epilepsy syndrome	2.85e-06	4.83e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MEF2C—epilepsy syndrome	2.84e-06	4.82e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—BDKRB2—epilepsy syndrome	2.84e-06	4.82e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CXCL12—epilepsy syndrome	2.84e-06	4.82e-05	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—POMC—epilepsy syndrome	2.84e-06	4.81e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PRKCB—epilepsy syndrome	2.83e-06	4.8e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GLUL—epilepsy syndrome	2.82e-06	4.78e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—IL6ST—epilepsy syndrome	2.82e-06	4.78e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—JUNB—epilepsy syndrome	2.79e-06	4.73e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CNR1—epilepsy syndrome	2.79e-06	4.73e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PLCB1—epilepsy syndrome	2.78e-06	4.71e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CACNA1D—epilepsy syndrome	2.77e-06	4.7e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—YWHAZ—epilepsy syndrome	2.75e-06	4.66e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HTR7—epilepsy syndrome	2.72e-06	4.61e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NGF—epilepsy syndrome	2.72e-06	4.61e-05	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—PRKCB—epilepsy syndrome	2.7e-06	4.59e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PTK2B—epilepsy syndrome	2.7e-06	4.57e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TSC1—epilepsy syndrome	2.7e-06	4.57e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—KCNJ11—epilepsy syndrome	2.68e-06	4.55e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CHRM3—epilepsy syndrome	2.68e-06	4.55e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—AGT—epilepsy syndrome	2.66e-06	4.51e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CCR5—epilepsy syndrome	2.64e-06	4.48e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HBEGF—epilepsy syndrome	2.64e-06	4.48e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCR2—epilepsy syndrome	2.62e-06	4.45e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SST—epilepsy syndrome	2.62e-06	4.45e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NTRK2—epilepsy syndrome	2.62e-06	4.45e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—DUSP6—epilepsy syndrome	2.6e-06	4.41e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—AKT3—epilepsy syndrome	2.59e-06	4.4e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—TXNRD1—epilepsy syndrome	2.59e-06	4.39e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—HTR2A—epilepsy syndrome	2.59e-06	4.39e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—POMC—epilepsy syndrome	2.58e-06	4.37e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ADRA2A—epilepsy syndrome	2.57e-06	4.35e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PLAT—epilepsy syndrome	2.56e-06	4.34e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ADAM10—epilepsy syndrome	2.53e-06	4.29e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CCL2—epilepsy syndrome	2.52e-06	4.27e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—AQP1—epilepsy syndrome	2.51e-06	4.26e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CXCL12—epilepsy syndrome	2.47e-06	4.18e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—BDKRB2—epilepsy syndrome	2.47e-06	4.18e-05	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—POMC—epilepsy syndrome	2.46e-06	4.18e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TSC2—epilepsy syndrome	2.46e-06	4.17e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PRKCB—epilepsy syndrome	2.46e-06	4.16e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—AGT—epilepsy syndrome	2.46e-06	4.16e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—IL6ST—epilepsy syndrome	2.45e-06	4.15e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—JUNB—epilepsy syndrome	2.42e-06	4.11e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CNR1—epilepsy syndrome	2.42e-06	4.11e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—epilepsy syndrome	2.41e-06	4.09e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PLCB1—epilepsy syndrome	2.41e-06	4.09e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—APOE—epilepsy syndrome	2.41e-06	4.08e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—S100B—epilepsy syndrome	2.39e-06	4.06e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SOCS3—epilepsy syndrome	2.37e-06	4.02e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CDC42—epilepsy syndrome	2.37e-06	4.01e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HTR7—epilepsy syndrome	2.36e-06	4.01e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—KDR—epilepsy syndrome	2.36e-06	4e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HBEGF—epilepsy syndrome	2.29e-06	3.89e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—AVP—epilepsy syndrome	2.29e-06	3.88e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CHRM3—epilepsy syndrome	2.27e-06	3.86e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—KCNJ11—epilepsy syndrome	2.27e-06	3.86e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PRKCB—epilepsy syndrome	2.27e-06	3.85e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IL6ST—epilepsy syndrome	2.26e-06	3.83e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—AKT3—epilepsy syndrome	2.25e-06	3.82e-05	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—AKT1—epilepsy syndrome	2.25e-06	3.81e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—POMC—epilepsy syndrome	2.24e-06	3.79e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ADAM10—epilepsy syndrome	2.2e-06	3.73e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CCL2—epilepsy syndrome	2.19e-06	3.71e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ABCG2—epilepsy syndrome	2.19e-06	3.71e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HES1—epilepsy syndrome	2.17e-06	3.67e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYP2C19—epilepsy syndrome	2.13e-06	3.62e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYP11A1—epilepsy syndrome	2.12e-06	3.59e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—AGT—epilepsy syndrome	2.12e-06	3.59e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—FYN—epilepsy syndrome	2.11e-06	3.57e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—H2AFX—epilepsy syndrome	2.1e-06	3.56e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MEF2C—epilepsy syndrome	2.09e-06	3.55e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—S100B—epilepsy syndrome	2.08e-06	3.53e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—epilepsy syndrome	2.07e-06	3.52e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—POMC—epilepsy syndrome	2.07e-06	3.5e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SOCS3—epilepsy syndrome	2.06e-06	3.49e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CDC42—epilepsy syndrome	2.05e-06	3.48e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—YWHAZ—epilepsy syndrome	2.02e-06	3.43e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CCL2—epilepsy syndrome	2.02e-06	3.43e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NGF—epilepsy syndrome	2e-06	3.39e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—AVP—epilepsy syndrome	1.99e-06	3.37e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCR5—epilepsy syndrome	1.95e-06	3.3e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HTR2A—epilepsy syndrome	1.91e-06	3.23e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HES1—epilepsy syndrome	1.88e-06	3.19e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ABCG2—epilepsy syndrome	1.85e-06	3.14e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—FYN—epilepsy syndrome	1.83e-06	3.1e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—FGF2—epilepsy syndrome	1.83e-06	3.1e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—H2AFX—epilepsy syndrome	1.82e-06	3.09e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ADRA2A—epilepsy syndrome	1.82e-06	3.09e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MEF2C—epilepsy syndrome	1.82e-06	3.08e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—BCHE—epilepsy syndrome	1.81e-06	3.07e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TSC2—epilepsy syndrome	1.81e-06	3.07e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—AGT—epilepsy syndrome	1.81e-06	3.07e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP2C19—epilepsy syndrome	1.81e-06	3.06e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP11A1—epilepsy syndrome	1.8e-06	3.04e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—POMC—epilepsy syndrome	1.78e-06	3.02e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—APOE—epilepsy syndrome	1.77e-06	3e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—YWHAZ—epilepsy syndrome	1.76e-06	2.98e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NGF—epilepsy syndrome	1.74e-06	2.95e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—KDR—epilepsy syndrome	1.74e-06	2.94e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—SLC2A1—epilepsy syndrome	1.73e-06	2.93e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PLCB1—epilepsy syndrome	1.71e-06	2.9e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—TH—epilepsy syndrome	1.7e-06	2.89e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—RELA—epilepsy syndrome	1.7e-06	2.88e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCR5—epilepsy syndrome	1.69e-06	2.87e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PRKCB—epilepsy syndrome	1.67e-06	2.83e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL6ST—epilepsy syndrome	1.66e-06	2.82e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MTOR—epilepsy syndrome	1.66e-06	2.82e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—epilepsy syndrome	1.63e-06	2.76e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP2D6—epilepsy syndrome	1.62e-06	2.75e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TSC2—epilepsy syndrome	1.57e-06	2.67e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—AGT—epilepsy syndrome	1.57e-06	2.66e-05	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—AKT1—epilepsy syndrome	1.54e-06	2.62e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ADRA2A—epilepsy syndrome	1.54e-06	2.62e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—APOE—epilepsy syndrome	1.54e-06	2.61e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—BCHE—epilepsy syndrome	1.54e-06	2.6e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CASP3—epilepsy syndrome	1.53e-06	2.59e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—POMC—epilepsy syndrome	1.52e-06	2.58e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—KDR—epilepsy syndrome	1.51e-06	2.56e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCL2—epilepsy syndrome	1.49e-06	2.53e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—JUN—epilepsy syndrome	1.49e-06	2.52e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SLC2A1—epilepsy syndrome	1.47e-06	2.48e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PRKCB—epilepsy syndrome	1.45e-06	2.46e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PLCB1—epilepsy syndrome	1.45e-06	2.46e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MMP9—epilepsy syndrome	1.45e-06	2.45e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL6ST—epilepsy syndrome	1.45e-06	2.45e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—TH—epilepsy syndrome	1.44e-06	2.45e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—HMOX1—epilepsy syndrome	1.42e-06	2.41e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	1.42e-06	2.41e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CAT—epilepsy syndrome	1.4e-06	2.38e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—AKT1—epilepsy syndrome	1.4e-06	2.38e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ABCB1—epilepsy syndrome	1.37e-06	2.32e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—FGF2—epilepsy syndrome	1.35e-06	2.28e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—SRC—epilepsy syndrome	1.33e-06	2.26e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—POMC—epilepsy syndrome	1.32e-06	2.24e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—VEGFA—epilepsy syndrome	1.3e-06	2.2e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCL2—epilepsy syndrome	1.29e-06	2.19e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GPX1—epilepsy syndrome	1.27e-06	2.15e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—RELA—epilepsy syndrome	1.25e-06	2.12e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MTOR—epilepsy syndrome	1.23e-06	2.08e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—HMOX1—epilepsy syndrome	1.21e-06	2.04e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CAT—epilepsy syndrome	1.19e-06	2.02e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—FGF2—epilepsy syndrome	1.17e-06	1.98e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ABCB1—epilepsy syndrome	1.16e-06	1.96e-05	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—AKT1—epilepsy syndrome	1.14e-06	1.93e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CASP3—epilepsy syndrome	1.13e-06	1.91e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—AGT—epilepsy syndrome	1.11e-06	1.89e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—JUN—epilepsy syndrome	1.09e-06	1.86e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—APOE—epilepsy syndrome	1.09e-06	1.85e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—RELA—epilepsy syndrome	1.08e-06	1.84e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GPX1—epilepsy syndrome	1.08e-06	1.82e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MMP9—epilepsy syndrome	1.06e-06	1.81e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MTOR—epilepsy syndrome	1.06e-06	1.8e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—AKT1—epilepsy syndrome	1.03e-06	1.75e-05	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—AKT1—epilepsy syndrome	9.88e-07	1.67e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SRC—epilepsy syndrome	9.82e-07	1.66e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CASP3—epilepsy syndrome	9.79e-07	1.66e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—VEGFA—epilepsy syndrome	9.56e-07	1.62e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—JUN—epilepsy syndrome	9.5e-07	1.61e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—AGT—epilepsy syndrome	9.43e-07	1.6e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—POMC—epilepsy syndrome	9.37e-07	1.59e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MMP9—epilepsy syndrome	9.25e-07	1.57e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—APOE—epilepsy syndrome	9.24e-07	1.57e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—AKT1—epilepsy syndrome	8.97e-07	1.52e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ALB—epilepsy syndrome	8.54e-07	1.45e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SRC—epilepsy syndrome	8.53e-07	1.45e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—VEGFA—epilepsy syndrome	8.3e-07	1.41e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—AKT1—epilepsy syndrome	8.29e-07	1.4e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—POMC—epilepsy syndrome	7.94e-07	1.35e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PTGS2—epilepsy syndrome	7.47e-07	1.27e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ALB—epilepsy syndrome	7.24e-07	1.23e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PTGS2—epilepsy syndrome	6.33e-07	1.07e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—AKT1—epilepsy syndrome	6.1e-07	1.03e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—AKT1—epilepsy syndrome	5.3e-07	8.98e-06	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—AKT1—epilepsy syndrome	3.76e-07	6.37e-06	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—AKT1—epilepsy syndrome	3.18e-07	5.4e-06	CbGpPWpGaD
